Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status

Parkinsonism and Related Disorders

Volumn 20, Issue 5, 2014, Pages 503-507

  Monsell, Sarah E ^a   Besser, Lilah M ^a   Heller, Katherine B ^a   Checkoway, Harvey ^b   Litvan, Irene ^c   Kukull, Walter A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

APOE; Clinical symptoms; Neuropathology; Parkinson's disease

Indexed keywords

AMYLOID; APOLIPOPROTEIN E4;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; CLINICAL DEMENTIA RATING; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; EPISODIC MEMORY; FEMALE; GENETIC ASSOCIATION; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPTOMATOLOGY; COGNITION DISORDERS; COMPLICATION; GENETICS; GENOTYPE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; COGNITION DISORDERS; DEMENTIA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84900010448     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.02.001     Document Type: Article

References (32)

1. Reiman E.M. In this issue: genetics, cholesterol, and the risk of Alzheimer's disease. JClin Psychiatry 2005, 66:938-939.
2. Cosentino S., Scarmeas N., Helzner E., Glymour M.M., Brandt J., Albert M., et al. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 2008, 70:1842-1849.
3. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
4. Campbell M.C., Markham J., Flores H., Hartlein J.M., Goate A.M., Cairns N.J., et al. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 2013, 81:520-527.
5. Federoff M., Jimenez-Rolando B., Nalls M.A., Singleton A.B. Alarge study reveals no association between APOE and Parkinson's disease. Neurobiol Dis 2012, 46:389-392.
6. Kurz M.W., Dekomien G., Nilsen O.B., Larsen J.P., Aarsland D., Alves G. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. JGeriatr Psychiatry Neurol 2009, 22:166-170.
7. Tsuang D., Leverenz J.B., Lopez O.L., Hamilton R.L., Bennett D.A., Schneider J.A., et al. APOE ε4 increases risk for dementia in pure synucleinopathies. JAm Med Assoc Neurol 2013, 70:223-228.
8. Gomperts S.N., Locascio J.J., Rentz D., Santarlasci A., Marquie M., Johnson K.A., et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013, 80:85-91.
9. Beekly D.L., Ramos E.M., Lee W.W., Deitrich W.D., Jacka M.E., Wu J., et al. The National Alzheimer's Coordinating Center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord 2007, 21:249-258.
10. Morris J.C., Weintraub S., Chui H.C., Cummings J., Decarli C., Ferris S., et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006, 20:210-216.
11. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
12. Wechsler D. WMS-R: Wechsler memory scale-revised manual 1987, Psychological Corp., Harcourt Brace Jovanovich.
13. Reitan R.M., Wolfson D. The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation 1993, Neuropsychology Press. 2nd ed.
14. Fahn S., Marsden C., Calne D., Goldstein M. Recent developments in Parkinson's disease 1987, Macmillan Health Care Information, Florham Park, NJ.
15. Levy G., Tang M.X., Cote L.J., Louis E.D., Alfaro B., Mejia H., et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000, 55:539-544.
16. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
17. Kaufer D.I., Cummings J.L., Ketchel P., Smith V., MacMillan A., Shelley T., et al. Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory. JNeuropsychiatry Clin Neurosci 2000, 12:233-239.
18. Ganguli M., Du Y., Dodge H.H., Ratcliff G.G., Chang C.-C.H. Depressive symptoms and cognitive decline in late life: a prospective epidemiological study. Arch Gen Psychiatry 2006, 63:153-160.
19. Holroyd S., Currie L., Wooten G.F. Prospective study of hallucinations and delusions in Parkinson's disease. JNeurol Neurosurg Psychiatr 2001, 70:734-738.
20. Lee A.H., Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord Off J Mov Disord Soc 2012, 27:858-863.
21. Kurtis M.M., Rodriguez-Blazquez C., Martinez-Martin P. Relationship between sleep disorders and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2013, 12:1152-1155. ELEP Group.
22. Liang K.-Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
23. Little R.J.A., Rubin D.B. Statistical analysis with missing data 2002, Wiley-Interscience. 2nd ed.
24. Van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007, 16:219-242.
25. Rubin D.B., Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med 1991, 10:585-598.
26. Storandt M., Head D., Fagan A.M., Holtzman D.M., Morris J.C. Toward a multifactorial model of Alzheimer disease. Neurobiol Aging 2012, 33:2262-2271.
27. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010, 67:122-131.
28. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
29. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berl) 2006, 112:389-404.
30. McKeith I.G., Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113-1124.
31. McKeith I.G., Dickson D.W., Lowe J., et al. Diagnosis and management of dementia with Lew bodies: Third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
32. Irwin D.J., White M.T., Toledo J.B., Xie S.X., Robinson J.L., Van Deerlin V., et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012, 72:587-598.